Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Wednesday . 9,073 shares changed hands during trading, an increase of 131% from the previous session’s volume of 3,931 shares.The stock last traded at $20.41 and had previously closed at $20.13.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft initiated coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price for the company. Finally, BTIG Research restated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Stock Up 2.2%

The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm has a fifty day moving average of $23.31 and a two-hundred day moving average of $25.98.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently made changes to their positions in AAPG. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the second quarter valued at about $391,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Ascentage Pharma Group International in the third quarter worth about $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the third quarter worth about $204,000. UBS Group AG raised its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, XY Capital Ltd raised its holdings in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.